484PThe addition of metformin to systemic anticancer therapy

ConclusionsIn conclusion, this meta-analysis of randomized, controlled phase II trials do not support clinical benefits of metformin added to systemic anticancer therapy in patients with advanced or metastatic cancer. However, further investigations including well-designed phase III trials are needed to resolve the issues (dose of metformin, treatment setting, particular cancer type, or immunomodulatory effect) on the addition of metformin to systemic anticancer therapy.Legal entity responsible for the studyJung Han Kim.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research